Company Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-10 EDT			5-day change	1st Jan Change
0.6227 ^USD	-2.70%		-16.42%	+11.20%

04-25	Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	CI
04-23	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohnâs and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Number of employees: 9

Managers	Title	Age	Since
Gabriele Cerrone CEO	Chief Executive Officer	52	98-02-10
Keeren Shah DFI	Director of Finance/CFO	47	-
Vaseem Palejwala CTO	Chief Tech/Sci/R&D Officer	-	16-12-31
Matthew Davis COO	Chief Operating Officer	-	22-06-30
Paul Spencer IRC	Investor Relations Contact	-	22-11-30
William Clementi PRN	Corporate Officer/Principal	-	23-08-31

Members of the board	Title	Age	Since
John Brancaccio BRD	Director/Board Member	76	20-06-30
Willy Simon BRD	Director/Board Member	72	15-10-31
Gabriele Cerrone CEO	Chief Executive Officer	52	98-02-10

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	194,612,289	63,373,729 ( 32.56 %)	0	32.56 %

Name	Equities	%	Valuation
Gabriele Cerrone 38.03 %	38,890,635	38.03 %	18 M $
Geode Capital Management LLC 0.2065 %	211,167	0.2065 %	95 870 $
HSBC Bank Plc 0.1606 %	164,226	0.1606 %	74 559 $
Morgan Stanley Capital Services LLC 0.1214 %	124,131	0.1214 %	56 355 $
Ausdal Financial Partners, Inc. 0.0545 %	55,700	0.0545 %	25 288 $
Zhang Financial LLC 0.0509 %	52,060	0.0509 %	23 635 $
EWA LLC 0.0425 %	43,476	0.0425 %	19 738 $
UBS Securities LLC 0.0273 %	27,949	0.0273 %	12 689 $
Bank of America, NA (Charlotte, North Carolina) 0.0264 %	27,011	0.0264 %	12 263 $
Barclays Bank Plc 0.0171 %	17,500	0.0171 %	7 945 $

Name	Equities	%	Valuation
ACCUSTEM SCIENCES, INC. 11.80%	1,337,970	11.80%	468,290 $

Tiziana Life Sciences Ltd.

14/15 Conduit Street

W1S 2XJ, London

http://www.tizianalifesciences.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
TIZIANA LIFE SCIENCES LTD	+11.20%	64.2M
MODERNA, INC.	+17.96%	47.02B
LONZA GROUP AG	+48.77%	41.86B
IQVIA HOLDINGS INC.	+1.17%	41.76B
CELLTRION, INC.	-4.27%	28.8B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.05B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.15B
BIO-TECHNE CORPORATION	+4.86%	12.55B
MEDPACE HOLDINGS, INC.	+27.29%	12.34B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.82B

Other Biotechnology & Medical Research